These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 15911936

  • 41. Escitalopram in the treatment of generalized anxiety disorder.
    Baldwin DS, Nair RV.
    Expert Rev Neurother; 2005 Jul; 5(4):443-9. PubMed ID: 16026227
    [Abstract] [Full Text] [Related]

  • 42. Power laws in covariability of anxiety and depression among newly diagnosed patients with major depressive episode, panic disorder and controls.
    Katerndahl DA.
    J Eval Clin Pract; 2009 Jun; 15(3):565-70. PubMed ID: 19522912
    [Abstract] [Full Text] [Related]

  • 43. Depression in Parkinson's disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation.
    da Silva TM, Munhoz RP, Alvarez C, Naliwaiko K, Kiss A, Andreatini R, Ferraz AC.
    J Affect Disord; 2008 Dec; 111(2-3):351-9. PubMed ID: 18485485
    [Abstract] [Full Text] [Related]

  • 44. [Difficulties in the diagnosis and treatment of major depressive disorder with comorbid anxiety symptoms].
    Akkaya C.
    Turk Psikiyatri Derg; 2006 Dec; 17(2):139-46. PubMed ID: 16755414
    [Abstract] [Full Text] [Related]

  • 45. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients.
    Boulenger JP, Huusom AK, Florea I, Baekdal T, Sarchiapone M.
    Curr Med Res Opin; 2006 Jul; 22(7):1331-41. PubMed ID: 16834832
    [Abstract] [Full Text] [Related]

  • 46. Suicide rates in short-term randomized controlled trials of newer antidepressants.
    Hammad TA, Laughren TP, Racoosin JA.
    J Clin Psychopharmacol; 2006 Apr; 26(2):203-7. PubMed ID: 16633153
    [Abstract] [Full Text] [Related]

  • 47. Outcome and impact of mental disorders in primary care at 5 years.
    Jackson JL, Passamonti M, Kroenke K.
    Psychosom Med; 2007 Apr; 69(3):270-6. PubMed ID: 17401055
    [Abstract] [Full Text] [Related]

  • 48. Symptomatic and syndromal anxiety in chronic forms of major depression: effect of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination.
    Ninan PT, Rush AJ, Crits-Christoph P, Kornstein SG, Manber R, Thase ME, Trivedi MH, Rothbaum BO, Zajecka J, Borian FE, Keller MB.
    J Clin Psychiatry; 2002 May; 63(5):434-41. PubMed ID: 12025827
    [Abstract] [Full Text] [Related]

  • 49. Putative Antidepressant Effect of Chamomile (Matricaria chamomilla L.) Oral Extract in Subjects with Comorbid Generalized Anxiety Disorder and Depression.
    Amsterdam JD, Li QS, Xie SX, Mao JJ.
    J Altern Complement Med; 2020 Sep; 26(9):813-819. PubMed ID: 31808709
    [Abstract] [Full Text] [Related]

  • 50. An open-label study of nefazodone treatment of major depression in patients with congestive heart failure.
    Lespérance F, Frasure-Smith N, Laliberté MA, White M, Lafontaine S, Calderone A, Talajic M, Rouleau JL.
    Can J Psychiatry; 2003 Nov; 48(10):695-701. PubMed ID: 14674053
    [Abstract] [Full Text] [Related]

  • 51. Assessing onset of treatment benefit in depression and anxiety: conceptual considerations.
    Laska EM, Mallinckrodt CH, Mundt JC, Leber P, Vaccarino AL, Kalali AH, Greist JH.
    J Clin Psychiatry; 2009 Aug; 70(8):1138-45. PubMed ID: 19758524
    [Abstract] [Full Text] [Related]

  • 52. Case study: nefazodone for juvenile mood disorders.
    Wilens TE, Spencer TJ, Biederman J, Schleifer D.
    J Am Acad Child Adolesc Psychiatry; 1997 Apr; 36(4):481-5. PubMed ID: 9100422
    [Abstract] [Full Text] [Related]

  • 53. Nefazodone treatment of major depression in alcohol-dependent patients: a double-blind, placebo-controlled trial.
    Roy-Byrne PP, Pages KP, Russo JE, Jaffe C, Blume AW, Kingsley E, Cowley DS, Ries RK.
    J Clin Psychopharmacol; 2000 Apr; 20(2):129-36. PubMed ID: 10770449
    [Abstract] [Full Text] [Related]

  • 54. [Current treatment of depression and agitation in the elderly -- clinical use of trazodone].
    Osváth P.
    Neuropsychopharmacol Hung; 2013 Sep; 15(3):147-55. PubMed ID: 24108179
    [Abstract] [Full Text] [Related]

  • 55. [Depression and professional activity: results of the NEXTEP study].
    Raffaitin F, Caparros Panduro C, Biro G, Dardennes R.
    Encephale; 2011 Feb; 37(1):59-67. PubMed ID: 21349376
    [Abstract] [Full Text] [Related]

  • 56. Chronic depression: medication (nefazodone) or psychotherapy (CBASP) is effective when the other is not.
    Schatzberg AF, Rush AJ, Arnow BA, Banks PL, Blalock JA, Borian FE, Howland R, Klein DN, Kocsis JH, Kornstein SG, Manber R, Markowitz JC, Miller I, Ninan PT, Rothbaum BO, Thase ME, Trivedi MH, Keller MB.
    Arch Gen Psychiatry; 2005 May; 62(5):513-20. PubMed ID: 15867104
    [Abstract] [Full Text] [Related]

  • 57. An open-label clinical trial of nefazodone in hypochondriasis.
    Kjernisted KD, Enns MW, Lander M.
    Psychosomatics; 2002 May; 43(4):290-4. PubMed ID: 12189254
    [Abstract] [Full Text] [Related]

  • 58. Concordance between clinicians' and patients' ratings of anxiety and depression as mediated by private self-consciousness.
    Deluty BM, Deluty RH, Carver CS.
    J Pers Assess; 1986 May; 50(1):93-106. PubMed ID: 3723316
    [Abstract] [Full Text] [Related]

  • 59. Nefazodone relief of alprazolam interdose dysphoria: a potential therapeutic benefit of 3A3/4 inhibition.
    Ketter TA, Callahan AM, Post R.
    J Clin Psychiatry; 1996 Jul; 57(7):307. PubMed ID: 8666573
    [No Abstract] [Full Text] [Related]

  • 60. Mood swings in patients with anxiety disorders compared with normal controls.
    Bowen R, Clark M, Baetz M.
    J Affect Disord; 2004 Mar; 78(3):185-92. PubMed ID: 15013242
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.